Cerevance Presents at The Federation of European Neuroscience Societies (FENS) Forum 2024

BOSTON, June 18, 2024 (GLOBE NEWSWIRE) — Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, will deliver a poster presentation at the upcoming Federation of European Neuroscience Societies (FENS) Forum 2024, taking place in Vienna, Austria, from June 25 – 29, 2024.

Presentation details

Title: NETSseq Enhances the Understanding of Cerebellar Transcriptomic Changes in Ataxia-Telangiectasia
Overview: Ataxia-telangiectasia (A-T) is a rare neurodegenerative disease caused by mutations in the A-T mutated gene, leading to progressive neurological issues. Using Cerevance’s NETSseq platform, RNA from purified cerebellar cell types of A-T and control donors was analyzed and subsequently revealed significant astrocyte gene expression changes related to inflammation and immune response. These cell type-specific pathways that are altered in disease provide insights into molecular mechanisms and potential future drug targets.
Presenter: Jenna Harvey, PhD
Session: Poster Session 06 – Section 129
Session Date and Time: Friday, June 28^th from 2:00 – 5:30 pm / poster presentation 2:00 – 3:30pm
Poster Number: PS06-28PM-582

About Cerevance
Cerevance is focused on the development of precision treatments for central nervous system (CNS) disorders, including chronic neurodegenerative conditions such as Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Utilizing a large and growing repository of over 15,000 human brain tissue samples, Cerevance is generating an unprecedented level of expression and epigenetic data thereby enabling the company to identify the most promising targets for the next generation of treatments for CNS disorders.

The company uses its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform and advanced machine learning techniques to uncover the gene expression profiles of select cell types to identify novel targets that are uniquely expressed in relevant circuits affected by diseases or are altered in disease states. With the information obtained from its research, combined with the expertise of its team of scientists and drug developers, Cerevance is advancing multiple therapeutics through clinical development, with CVN424, CVN766, and CVN293 being the furthest along in the pipeline. CVN424 is a first-in-class non-dopamine therapy that shows promise in improving both motor and non-motor symptoms of Parkinson’s disease and may also have disease-delaying effects. CVN766 is a potent and highly selective antagonist of the orexin 1 receptor which may benefit various psychiatric conditions including schizophrenia, anxiety/panic, binge eating/obesity, substance use disorder, and Prader-Willi Syndrome. CVN293 is a novel blocker of potassium efflux in glia, regulating the inflammasome in individuals living with neurodegenerative diseases.

Cerevance’s robust pipeline aims to transform the lives of patients affected by CNS diseases.

Contacts

Cerevance:
Johnna Simoes, ir@cerevance.com

Media:
Andrew Mielach, amielach@lifescicomms.com, +1-646-876-5868